KBC Group NV Sells 2,974 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

KBC Group NV decreased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 34.4% during the third quarter, Holdings Channel reports. The fund owned 5,661 shares of the biotechnology company’s stock after selling 2,974 shares during the period. KBC Group NV’s holdings in BioCryst Pharmaceuticals were worth $43,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Aigen Investment Management LP lifted its stake in shares of BioCryst Pharmaceuticals by 75.0% in the third quarter. Aigen Investment Management LP now owns 28,661 shares of the biotechnology company’s stock worth $218,000 after buying an additional 12,280 shares in the last quarter. Principal Financial Group Inc. raised its stake in BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after acquiring an additional 375,890 shares during the period. Rice Hall James & Associates LLC boosted its holdings in BioCryst Pharmaceuticals by 4.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock worth $16,444,000 after buying an additional 84,102 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in BioCryst Pharmaceuticals by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,791 shares of the biotechnology company’s stock valued at $302,000 after purchasing an additional 15,544 shares during the period. Finally, Semanteon Capital Management LP bought a new position in shares of BioCryst Pharmaceuticals during the third quarter worth $1,137,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $7.60 on Friday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -12.46 and a beta of 1.89. The stock’s fifty day moving average price is $7.66 and its 200 day moving average price is $7.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same period in the prior year, the business posted ($0.19) earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was up 35.1% on a year-over-year basis. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Barclays lifted their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and issued a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Finally, JMP Securities lifted their target price on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.